Combination of Toripalimab and JS004 Therapy for ccRCC — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Combination of Toripalimab and JS004 Therapy for ccRCC — Stella

Recruiting

Back to Clear Cell Renal Cell Carcinoma trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

China

Fudan University Shanghai Cancer Center, Shanghai, Shanghai Municipality

Key details

Phase

Safety & dosing

Sponsor

Fudan University

Enrollment target

~80 participants

Started

June 2024

Primary completion

June 2026

Age range

18 Years and older

Last updated November 2024

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov